Dec 13, 03:01 AM

Suven Pharma to Acquire NJ Bio for $64 Million, Plans 600 Retail Stores and Receives Buy Recommendation

Suven Pharma, owned by Advent International, is pursuing mergers and acquisitions to enhance its technological capabilities and expand its order book. The company has announced plans to acquire a majority stake in NJ Bio for $64 million. This acquisition is part of a broader strategy by Advent International to implement significant changes at Suven Pharma, including a management overhaul. Additionally, Suven Pharma plans to open 600 retail stores by FY2026, indicating a robust growth trajectory. Analysts have issued a 'buy' recommendation for the company, suggesting confidence in its future performance.

#Suven Pharma #Advent International #NJ Bio

Written with ChatGPT (GPT-4o mini).

Sources

Moneycontrol@moneycontrolcom
2 years ago
#MCOpinionPro | PE firm Advent Intnl has been making several changes at Suven Pharma after acquiring it, including management recast. Its latest acquisition of NJ Bio is the latest example. 🏢💰🔄 Will these acquisitions deliver for investors? by @Sree_rsr… https://t.co/RbpSMdcRNS
Salil@salilkallianpur
2 years ago
Suven Pharma sets sights on M&As to scale up tech expertise & order book https://t.co/8Yb2eJkEU1
ET NOW@ETNOWlive
2 years ago
THIS pharma company plans to open 600 retail stores in FY2026; gets BUY call https://t.co/EmVkyLGPOV

Suven Pharma to Acquire NJ Bio for $64 Million, Plans 600 Retail Stores and Receives Buy Recommendation

Sources

Additional media

Similar Stories